Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Heterozygous Familial Hypercholesterolemia Clinical Trial

Official title:

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03038022
• Other study ID #: MGL-3196-06
• Status: Completed
• Phase: Phase 2
• First received: January 30, 2017
• Last updated: January 23, 2018
• Start date: February 9, 2017
• Est. completion date: January 15, 2018

Study information

• Verified date: January 2018
• Source: Madrigal Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 116
• Est. completion date: January 15, 2018
• Est. primary completion date: December 18, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be willing to participate in the study and provide written informed consent;

• Male and female adults =18 years of age;

• Female patients of child bearing potential with negative serum pregnancy (beta human chorionic gonadotropin) test who are not breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control (ie, condoms, diaphragm, non-hormonal intrauterine device [IUD], or sexual abstinence [only if this is in line with the patient's current lifestyle]) throughout the study and for at least 1 month after study completion; hormonal contraception (estrogens stable =3 months) and hormonal IUDs are permitted if used with a secondary birth control measure (eg, condoms); OR female patients of non-child bearing potential (ie, surgically [bilateral oophorectomy, hysterectomy, or tubal ligation] or naturally sterile [>12 consecutive months without menses]); male patients who have sexual intercourse with a female partner of child bearing potential from the first dose of study drug until 1 month after study completion must either be surgically sterile (confirmed by documented azoospermia >90 days after the procedure) OR agree to use a condom with spermicide. All male patients must agree not to donate sperm from the first dose of study drug until 1 month after study completion;

• Must have a diagnosis of HeFH by genetic testing or by having met the diagnostic criteria for definite familial hypercholesterolemia outlined by the Simon Broome Register Group or WHO/Dutch Lipid Network (score >8);

• Must have a fasting LDL-C = 2.6 mmol/L (100 mg/dL); and

• Must be on a stable or maximally tolerated dose (= 4 weeks prior to screening) of an approved statin (rosuvastatin = 20 mg daily, atorvastatin = 80 mg daily), with or without ezetimibe.

Exclusion Criteria:

• Homozygous familial hypercholesterolemia

• Low-density lipoprotein (LDL) or plasma apheresis within 2 months prior to randomization;

• New York Heart Association class III or IV heart failure, or known left ventricular ejection fraction <30%;

• Uncontrolled cardiac arrhythmia, including confirmed QT interval corrected using Fridericia's formula (QTcF) >450 msec for males and >470 msec for females at the screening electrocardiogram (ECG) assessment;

• Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within 3 months prior to randomization;

• Type 1 diabetes, or newly diagnosed or uncontrolled type 2 diabetes (hemoglobin A1c [HbA1c] >8%);

• History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening; Note: Significant alcohol consumption is defined as average of >20 g/day in female patients and >30 g/day in male patients;

• Thyroid replacement therapy;

• Evidence of chronic liver disease;

• Hepatitis B, as defined by the presence of hepatitis B surface antigen;

• Hepatitis C, as defined by the presence of hepatitis C virus (HCV) antibody (anti-HCV) and HCV ribonucleic acid (RNA). Patients with positive anti-HCV who test negative for HCV RNA at screening will be allowed to participate in the study;

• Serum alanine aminotransferase (ALT) >1.5 × ULN (one repeat allowed);

• Estimated glomerular filtration rate <60 mL/min;

• Creatine kinase >3 × ULN (one repeat allowed);

• History of biliary diversion;

• Positive for human immunodeficiency virus infection;

• History of malignant hypertension;

• Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening or randomization and confirmed at an unscheduled visit;

• Triglycerides >5.7 mmol/L (500 mg/dL) at screening and confirmed by repeat assessment;

• Active, serious medical disease with likely life expectancy <2 years;

• Active substance abuse, including inhaled or injection drugs within the year prior to screening;

• Participation in an investigational new drug trial within the 30 days prior to randomization; or

• Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, or compromise the well-being of the patient.

Related Conditions & MeSH terms

• Heterozygous Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipoproteinemia Type II

Intervention

Drug:
• MGL-3196
Oral
• Placebo
Oral

Locations

Country	Name	City	State
Denmark	Madrigal Research Site	Aalborg
Denmark	Madrigal Research Site	Viborg

Sponsors (1)

Lead Sponsor	Collaborator
Madrigal Pharmaceuticals, Inc.

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C)		12 Weeks
Secondary	Safety and tolerability of MGL-3196 based on Adverse Events and Changes in Laboratory Values		12 Weeks
Secondary	Mean percent change from baseline on selected lipid parameters	Non-high-density lipoprotein cholesterol (non-HDL-C),Apolipoprotein B (ApoB), Total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) ratio, Triglycerides,Lipoprotein(a), Apolipoprotein A1 (ApoA1)/ApoB ratio, and Lipoprotein particle assessment	12 Weeks